Zoetis
Simparica 120 mg for dogs between 40 and 60 kg 3 chewable tablets

Treatment of mixed infestations by internal or external parasites in dogs

Prescription required* (Exceptions apply)

Simparica are chewable tablets for use in dogs.

Simparica:

  • Each tablet contains:

    • Active substance:
Name Sarolaner (mg)
Simparica 5 mg chewable tablets for dogs 1.3–2.5 kg 5
Simparica 10 mg chewable tablets for dogs >2.5–5 kg 10
Simparica 20 mg chewable tablets for dogs >5–10 kg 20
Simparica 40 mg chewable tablets for dogs >10–20 kg 40
Simparica 80 mg chewable tablets for dogs >20–40 kg 80
Simparica 120 mg chewable tablets for dogs >40–60 kg 120
  • Excipients:
    • Hypromellose acetate succinate, medium grade
    • Lactose monohydrate
    • Sodium starch glycolate
    • Silica, colloidal anhydrous
    • Magnesium stearate
    • Maize starch
    • Confectioner’s sugar
    • Glucose, liquid (81.5% solids)
    • Spray dried pork liver powder
    • Hydrolysed vegetable protein
    • Gelatin type A
    • Wheat germ
    • Calcium hydrogen phosphate anhydrous

Simparica Trio:

  • Each tablet contains:

    • Active substance:
Name Sarolaner (mg) Moxidectin (mg) Pyrantel (as embonate) (mg)
Simparica Trio chewable tablets for dogs 1.25–2.5 kg 3 0.06 12.5
Simparica Trio chewable tablets for dogs >2.5–5 kg 6 0.12 25
Simparica Trio chewable tablets for dogs >5–10 kg 12 0.24 50
Simparica Trio chewable tablets for dogs >10–20 kg 24 0.48 100
Simparica Trio chewable tablets for dogs >20–40 kg 48 0.96 200
Simparica Trio chewable tablets for dogs >40–60 kg 72 1.44 300
  • Excipients:
    • Hypromellose
    • Lactose monohydrate
    • Sodium starch glycolate type A
    • Meglumine
    • Butylhydroxytoluene (E321)
    • Pigment blend 018 (E110, E129, E132)
    • Hydroxypropylcellulose
    • Silica, colloidal anhydrous
    • Magnesium stearate
    • Maize starch
    • Confectioner’s sugar
    • Glucose, liquid
    • Pork liver powder
    • Hydrolysed vegetable protein
    • Gelatin
    • Wheat germ
    • Calcium hydrogen phosphate anhydrous

Simparica:

  • Is indicated for the treatment of tick infestations (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus). The veterinary medicinal product has immediate and persistent tick killing activity for at least 5 weeks.
  • Is indicated for the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis). The veterinary medicinal product has immediate and persistent flea killing activity against new infestations for at least 5 weeks. The veterinary medicinal product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD).
  • Is indicated for the treatment of sarcoptic mange (Sarcoptes scabiei).
  • Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
  • Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Simparica Trio:

  • For dogs with, or at risk from, mixed external and internal parasitic infestations. The veterinary medicinal product is exclusively indicated when use against ticks or fleas and gastrointestinal nematodes is indicated at the same time. The veterinary medicinal product also provides concurrent efficacy for the prevention of heartworm disease and angiostrongylosis.

  • Ectoparasites:

    • For the treatment of tick infestations. The veterinary medicinal product has immediate and persistent tick killing activity for 5 weeks against Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus and for 4 weeks against Dermacentor reticulatus;
    • For the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis). The veterinary medicinal product has immediate and persistent flea killing activity against new infestations for 5 weeks;
    • The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
  • Gastrointestinal nematodes:

    • For the treatment of gastrointestinal roundworm and hookworm infections:
    • Toxocara canis immature adults (L5) and adults;
    • Ancylostoma caninum L4 larvae, immature adults (L5) and adults;
    • Toxascaris leonina adults;
    • Uncinaria stenocephala adults.
  • Other nematodes:
    • For the prevention of heartworm disease (Dirofilaria immitis);
    • For the prevention of angiostrongylosis by reducing the level of infection with immature adult (L5) stages of Angiostrongylus vasorum.

Simparica:

  • For oral use.
  • Tablets can be administered with or without food.
  • The veterinary medicinal product should be administered at a dose of 2–4 mg/kg bodyweight in accordance with the following table:
Bodyweight(kg) Tablet strength (mg de sarolaner) Number of tablets to be administered
1.3 – 2.5 5 1
> 2.5 - 5 10 1
> 5 - 10 20 1
> 10 - 20 40 1
> 20 - 40 80 1
> 40 - 60 120 1
> 60 Appropriate combination of tablets
  • Use appropriate combination of available strengths to achieve the recommended dose of 2–4 mg/kg.
  • Simparica tablets are chewable and palatable and readily consumed by dogs when offered by the owner. If the tablet is not taken up voluntarily by the dog it can also be given with food or directly into the mouth. The tablets should not be divided.
  • Treatment schedule:
    • For optimal control of tick and fleas infestations, the veterinary medicinal product should be administered at monthly intervals and continue throughout the flea and/or tick season based on local epidemiological situations.
    • For the treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis) a single dose should be administered at monthly intervals for two consecutive months.

Simparica Trio:

  • Oral use.
  • The veterinary medicinal product should be administered at a dose of 1.2–2.4 mg/kg of sarolaner, 0.024–0.048 mg/kg of moxidectin and 5–10 mg/kg of pyrantel in accordance with the following table:
Bodyweight (kg) Tablet strength 3 mg/0.06 mg/ 12.5 mg Tablet strength 6 mg/0.12 mg/ 25 mg Tablet strength 12 mg/0.24 mg/50 mg Tablet strength 24 mg/0.48 mg/100 mg Tablet strength 48 mg/0.96 mg/200 mg Tablet strength 72 mg/1.44 mg/300 mg
1.25–2.5 kg 1
>2.5–5 kg 1
>5–10 kg 1
>10–20 kg 1
>20–40 kg 1
>40–60 kg 1
>60 kg Appropriate combination of tablets
  • Method of administration:

    • Tablets can be administered with or without food.
    • Simparica Trio tablets are palatable and readily consumed by the majority of dogs when offered by the owner. If the tablet is not taken up voluntarily by the dog it can also be given with food or directly into the mouth. The tablets should not be divided.
  • Treatment schedule:
    • The treatment schedule should be based on veterinary diagnosis, the local epidemiological situation and/or the epidemiological situation of other areas the dog has visited or is going to visit. If based on veterinarian opinion re-administration(s) of the product is required, any subsequent administration(s) must follow the minimum 1-month interval schedule.
  • The product should only be used in dogs when treatment of ticks / fleas and gastrointestinal nematodes is indicated at the same time. In the absence of the risk of mixed co-infestation, a narrower spectrum parasiticide should be used.

  • Treatment of flea and tick infestations and gastrointestinal nematodes:

    • The veterinary medicinal product can be used as part of the seasonal treatment of fleas and ticks (replacing treatment with a mono-active flea and tick product) in dogs with diagnosed concurrent gastrointestinal nematode infections. A single treatment is efficacious for the treatment of gastrointestinal nematodes. After treatment of the nematode infections, further flea and tick treatment should be continued with a mono-active product.
  • Prevention of heartworm disease and angiostrongylosis:
    • A single administration also prevents lungworm disease (by reducing the immature adults (L5) of A. vasorum) and heartworm disease (D. immitis) for one month. When the product replaces another lungworm or heartworm preventive product, the first dose of the product should be given within a month of the last dose of the former veterinary medicinal product. In endemic areas, dogs should receive lungworm and/or heartworm preventive treatments at monthly intervals. It is recommended that heartworm prevention treatment should be continued until at least 1 month after the last exposure to mosquitoes.

Simparica are chewable tablets for use in dogs.

Simparica:

  • Each tablet contains:

    • Active substance:
Name Sarolaner (mg)
Simparica 5 mg chewable tablets for dogs 1.3–2.5 kg 5
Simparica 10 mg chewable tablets for dogs >2.5–5 kg 10
Simparica 20 mg chewable tablets for dogs >5–10 kg 20
Simparica 40 mg chewable tablets for dogs >10–20 kg 40
Simparica 80 mg chewable tablets for dogs >20–40 kg 80
Simparica 120 mg chewable tablets for dogs >40–60 kg 120
  • Excipients:
    • Hypromellose acetate succinate, medium grade
    • Lactose monohydrate
    • Sodium starch glycolate
    • Silica, colloidal anhydrous
    • Magnesium stearate
    • Maize starch
    • Confectioner’s sugar
    • Glucose, liquid (81.5% solids)
    • Spray dried pork liver powder
    • Hydrolysed vegetable protein
    • Gelatin type A
    • Wheat germ
    • Calcium hydrogen phosphate anhydrous

Simparica Trio:

  • Each tablet contains:

    • Active substance:
Name Sarolaner (mg) Moxidectin (mg) Pyrantel (as embonate) (mg)
Simparica Trio chewable tablets for dogs 1.25–2.5 kg 3 0.06 12.5
Simparica Trio chewable tablets for dogs >2.5–5 kg 6 0.12 25
Simparica Trio chewable tablets for dogs >5–10 kg 12 0.24 50
Simparica Trio chewable tablets for dogs >10–20 kg 24 0.48 100
Simparica Trio chewable tablets for dogs >20–40 kg 48 0.96 200
Simparica Trio chewable tablets for dogs >40–60 kg 72 1.44 300
  • Excipients:
    • Hypromellose
    • Lactose monohydrate
    • Sodium starch glycolate type A
    • Meglumine
    • Butylhydroxytoluene (E321)
    • Pigment blend 018 (E110, E129, E132)
    • Hydroxypropylcellulose
    • Silica, colloidal anhydrous
    • Magnesium stearate
    • Maize starch
    • Confectioner’s sugar
    • Glucose, liquid
    • Pork liver powder
    • Hydrolysed vegetable protein
    • Gelatin
    • Wheat germ
    • Calcium hydrogen phosphate anhydrous

Simparica:

  • Is indicated for the treatment of tick infestations (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus). The veterinary medicinal product has immediate and persistent tick killing activity for at least 5 weeks.
  • Is indicated for the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis). The veterinary medicinal product has immediate and persistent flea killing activity against new infestations for at least 5 weeks. The veterinary medicinal product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD).
  • Is indicated for the treatment of sarcoptic mange (Sarcoptes scabiei).
  • Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
  • Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Simparica Trio:

  • For dogs with, or at risk from, mixed external and internal parasitic infestations. The veterinary medicinal product is exclusively indicated when use against ticks or fleas and gastrointestinal nematodes is indicated at the same time. The veterinary medicinal product also provides concurrent efficacy for the prevention of heartworm disease and angiostrongylosis.

  • Ectoparasites:

    • For the treatment of tick infestations. The veterinary medicinal product has immediate and persistent tick killing activity for 5 weeks against Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus and for 4 weeks against Dermacentor reticulatus;
    • For the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis). The veterinary medicinal product has immediate and persistent flea killing activity against new infestations for 5 weeks;
    • The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
  • Gastrointestinal nematodes:

    • For the treatment of gastrointestinal roundworm and hookworm infections:
    • Toxocara canis immature adults (L5) and adults;
    • Ancylostoma caninum L4 larvae, immature adults (L5) and adults;
    • Toxascaris leonina adults;
    • Uncinaria stenocephala adults.
  • Other nematodes:
    • For the prevention of heartworm disease (Dirofilaria immitis);
    • For the prevention of angiostrongylosis by reducing the level of infection with immature adult (L5) stages of Angiostrongylus vasorum.

Simparica:

  • For oral use.
  • Tablets can be administered with or without food.
  • The veterinary medicinal product should be administered at a dose of 2–4 mg/kg bodyweight in accordance with the following table:
Bodyweight(kg) Tablet strength (mg de sarolaner) Number of tablets to be administered
1.3 – 2.5 5 1
> 2.5 - 5 10 1
> 5 - 10 20 1
> 10 - 20 40 1
> 20 - 40 80 1
> 40 - 60 120 1
> 60 Appropriate combination of tablets
  • Use appropriate combination of available strengths to achieve the recommended dose of 2–4 mg/kg.
  • Simparica tablets are chewable and palatable and readily consumed by dogs when offered by the owner. If the tablet is not taken up voluntarily by the dog it can also be given with food or directly into the mouth. The tablets should not be divided.
  • Treatment schedule:
    • For optimal control of tick and fleas infestations, the veterinary medicinal product should be administered at monthly intervals and continue throughout the flea and/or tick season based on local epidemiological situations.
    • For the treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis) a single dose should be administered at monthly intervals for two consecutive months.

Simparica Trio:

  • Oral use.
  • The veterinary medicinal product should be administered at a dose of 1.2–2.4 mg/kg of sarolaner, 0.024–0.048 mg/kg of moxidectin and 5–10 mg/kg of pyrantel in accordance with the following table:
Bodyweight (kg) Tablet strength 3 mg/0.06 mg/ 12.5 mg Tablet strength 6 mg/0.12 mg/ 25 mg Tablet strength 12 mg/0.24 mg/50 mg Tablet strength 24 mg/0.48 mg/100 mg Tablet strength 48 mg/0.96 mg/200 mg Tablet strength 72 mg/1.44 mg/300 mg
1.25–2.5 kg 1
>2.5–5 kg 1
>5–10 kg 1
>10–20 kg 1
>20–40 kg 1
>40–60 kg 1
>60 kg Appropriate combination of tablets
  • Method of administration:

    • Tablets can be administered with or without food.
    • Simparica Trio tablets are palatable and readily consumed by the majority of dogs when offered by the owner. If the tablet is not taken up voluntarily by the dog it can also be given with food or directly into the mouth. The tablets should not be divided.
  • Treatment schedule:
    • The treatment schedule should be based on veterinary diagnosis, the local epidemiological situation and/or the epidemiological situation of other areas the dog has visited or is going to visit. If based on veterinarian opinion re-administration(s) of the product is required, any subsequent administration(s) must follow the minimum 1-month interval schedule.
  • The product should only be used in dogs when treatment of ticks / fleas and gastrointestinal nematodes is indicated at the same time. In the absence of the risk of mixed co-infestation, a narrower spectrum parasiticide should be used.

  • Treatment of flea and tick infestations and gastrointestinal nematodes:

    • The veterinary medicinal product can be used as part of the seasonal treatment of fleas and ticks (replacing treatment with a mono-active flea and tick product) in dogs with diagnosed concurrent gastrointestinal nematode infections. A single treatment is efficacious for the treatment of gastrointestinal nematodes. After treatment of the nematode infections, further flea and tick treatment should be continued with a mono-active product.
  • Prevention of heartworm disease and angiostrongylosis:
    • A single administration also prevents lungworm disease (by reducing the immature adults (L5) of A. vasorum) and heartworm disease (D. immitis) for one month. When the product replaces another lungworm or heartworm preventive product, the first dose of the product should be given within a month of the last dose of the former veterinary medicinal product. In endemic areas, dogs should receive lungworm and/or heartworm preventive treatments at monthly intervals. It is recommended that heartworm prevention treatment should be continued until at least 1 month after the last exposure to mosquitoes.
33.54
55.90 €
Order within 9h 59m 59s (before 12AM)
And receive your order
on Friday 17 July
AIR FREIGHT

Customers who buy this product, usually buy: